文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症消化、代谢与肾脏急症

肠道菌群失调作为改善术后结局与患者管理的靶点:当前文献综述

Gut Microbiota Dysbiosis as a Target for Improved Post-Surgical Outcomes and Improved Patient Care: A Review of Current Literature.
PubMed 文献 · Shock · 2021-01-01
一句话结论综述指出重症患者肠道菌群严重失调参与脓毒症/ARDS术后并发症,益生菌、益生元和粪菌移植是ICU潜在干预策略,但操纵危重患者菌群可能具有挑战性。

该综述聚焦重症导致肠道菌群显著改变、肠屏障功能破坏,进而参与多器官功能障碍的发病机制。脓毒症/急性呼吸窘迫综合征(ARDS)患者肠道菌群节律严重紊乱,在肠道源性感染和肠道菌群失调中起相当作用。术后并发症与高发病率和高死亡率相关,细菌易位(细菌及细菌产物穿过肠屏障)被视为脓毒症背后的机制之一。当前研究关注通过解决导致肠道菌群失调的重要因素来减少多器官衰竭和死亡。综述基于已发表研究,讨论在ICU应用益生菌、益生元和粪菌移植等策略以减少重症患者脓毒症/ARDS术后并发症,但指出在危重患者中操纵菌群以增强治疗获益可能具有挑战性。

要点

  • 重症导致人肠道菌群显著改变,肠屏障功能破坏,参与多器官功能障碍的发病机制。
  • 脓毒症/ARDS患者肠道菌群节律严重紊乱,在肠道源性感染和肠道菌群失调中起相当作用。
  • 细菌易位(细菌及细菌产物穿过肠屏障)被视为脓毒症背后的机制之一。
  • 益生菌操纵有利于维持肠屏障防御和调节免疫反应。
  • 综述讨论在ICU应用益生菌、益生元和粪菌移植以减少重症患者脓毒症/ARDS术后并发症,但在危重患者中操纵菌群以增强治疗获益可能具有挑战性。

适用人群与场景

  • 重症患者,包括脓毒症/急性呼吸窘迫综合征(ARDS)患者。
  • 接受手术、存在术后并发症风险的重症患者。

处置流程与药物剂量

  • 综述讨论在ICU应用益生菌、益生元和粪菌移植等潜在策略,以减少重症患者脓毒症/ARDS术后并发症;原文未给出具体药物剂量、途径、频次或疗程。

研究设计与关键结果

  • 综述基于已发表研究,指出重症导致肠道菌群显著改变和肠屏障功能破坏,参与多器官功能障碍的发病机制。
  • 脓毒症/ARDS患者肠道菌群节律严重紊乱,在肠道源性感染和肠道菌群失调中起相当作用。
  • 细菌易位被视为脓毒症背后的机制之一。
  • 益生菌操纵有利于维持肠屏障防御和调节免疫反应。
  • 综述讨论在ICU应用益生菌、益生元和粪菌移植等策略以减少重症患者脓毒症/ARDS术后并发症,但指出在危重患者中操纵菌群以增强治疗获益可能具有挑战性。

证据类型、等级与局限

  • 证据类型:综述。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 综述提示益生菌操纵可能有利于维持肠屏障防御和调节免疫反应,并讨论益生菌、益生元和粪菌移植作为ICU潜在策略以减少重症患者脓毒症/ARDS术后并发症,但指出在危重患者中操纵菌群以增强治疗获益可能具有挑战性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Critical illness results in significant changes in the human gut microbiota, leading to the breakdown of the intestinal barrier function, which plays a role in the pathogenesis of multiple organ dysfunction. Patients with sepsis/acute respiratory distress syndrome (ARDS) have a profoundly distorted intestinal microbiota rhythm, which plays a considerable role in the development of gut-derived infections and intestinal dysbiosis. Despite recent medical developments, postsurgical complications are associated with a high morbidity and mortality rate. Bacterial translocation, which is the movement of bacteria and bacterial products across the intestinal barrier, was shown to be a mechanism behind sepsis. Current research is focusing on a solution by addressing significant factors that contribute to intestinal dysbiosis, which subsequently leads to multiple organ failure and, thus, mortality. It may, however, be challenging to manipulate the microbiota in critically ill patients for enhanced therapeutic gain. Probiotic manipulation is advantageous for maintaining the gut-barrier defense and for modulating the immune response. Based on available published research, this review aims to address the application of potential strategies in the intensive care unit, supplemented with current therapeutics by the administration of probiotics, prebiotics, and fecal microbiota transplant, to reduce post-surgical complications of sepsis/ARDS in critically ill patients.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Mustansir Dawoodbhoy F, Patel BK, Patel K, et al. Gut Microbiota Dysbiosis as a Target for Improved Post-Surgical Outcomes and Improved Patient Care: A Review of Current Literature. Shock. 2021. PMID: 32881759. doi:10.1097/SHK.0000000000001654

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。